Menu
Oslo, November 19, 2024: Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, today ships the first product samples of Thorium-228 alpha-emitters from its newly commissioned pilot facilities at Herøya. The shipment marks another important milestone in Thor Medical’s journey toward commercial operations.
“Since opening our pilot facilities at Herøya less than two months ago, our highest priority has been to ensure process and product quality. Targeted cancer care with alpha-emitters holds the potential to transform cancer treatment regimes, and this successful first production run marks another significant step towards commercially viable production of alpha-emitters”, says Jasper Kurth, CEO of Thor Medical.
The first Thorium-228 product samples are today being shipped to an undisclosed potential customer, one of several potential customers for supply of Thorium-228 from Thor Medical.
The first product shipment follows other recent key de-risking milestones, including the on-time and on-budget completion of the Herøya pilot facilities in September, and the signing of a strategic 5-year supply agreement for Thorium-228 with ARTBIO in October.
On 25 November, Thor Medical hosts a Capital Markets Update in Stockholm, including presentations from both Thor Medical and ARTBIO.
